The burden of age-related macular degeneration: Results of a cohort study in two french referral centres

PharmacoEconomics

Volumn 21, Issue 3, 2003, Pages 181-190

  Bonastre, Julia ^a   Le Pen, Claude ^a,b,e   Soubrane, Giséle ^c   Quentel, Gabriel ^d  

^a CLP Sante   (France)

^b UNIVERSITÉ PARIS DAUPHINE   (France)

^c UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^d Centre d'Imagerie et de Laser   (France)

^e CLP Sante   (France)

Author keywords

[No Author keywords available]

Indexed keywords

PERIPHERAL VASODILATING AGENT; TRIMETAZIDINE;

ADULT; AGE; AGED; ARTICLE; CONSULTATION; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DRUG COST; EXUDATE; FEMALE; FOLLOW UP; FRANCE; HEALTH CARE COST; HEALTH ECONOMICS; HOME CARE; HUMAN; LASER COAGULATION; MAJOR CLINICAL STUDY; MALE; PATIENT SELECTION; PATIENT TRANSPORT; PRIORITY JOURNAL; PRIVATE HEALTH INSURANCE; RETINA MACULA AGE RELATED DEGENERATION; SOCIAL SECURITY; VISUAL ACUITY; VISUAL AID; VISUAL IMPAIRMENT; WELFARE;

AGED; AGED, 80 AND OVER; AUDIOVISUAL AIDS; COHORT STUDIES; COST OF ILLNESS; FRANCE; HUMANS; MACULAR DEGENERATION; MIDDLE AGED; VISUAL ACUITY;

EID: 0037218226     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200321030-00003     Document Type: Article

References (43)

1. Arnold JJ, Sarks SH. Age related macular degeneration. Clin Evid 1999; 2: 247-54
2. Cohen SY. Le vieillissement maculaire et la dégénérescence maculaire liée à l'âge. In: Le vieillissement de l'œil et de ses annexes. Rapport annuel des Sociétés d'Ophtalmologie de France. Paris: Société d'Ophtalmologie de France, 1999: 319
3. Coscas G, Glaser B, Green W, et al. Dégd́nérescences maculaires acquises et néovaisseaux. Rapport annuel de la Société Française d'Ophtalmologie. Paris: Editions Masson, 1999
4. Soubrane G, Coscas G. Affections acquises de l'épithélium pigmentaire rétinien. Rapport annuel des Sociétés d'Ophtalmologie de France. Paris: Lamy, 1995
5. Allikmets R. Molecular genetics of age-related macular degeneration: current status. Eur J Ophthalmol 1999; 9 (4): 255-65
6. Klein R, Klein BE, Linton KL. Prevalence of age-related maculopathy: the Beaver Dam Eye Study. Ophthalmology 1992; 99 (6): 933-43
7. Kahn HA, Leibowitz HM, Ganley JP, et al. The Framingham Eye Study. I: outline and major prevalence findings. Am J Epidemiol 1977; 106: 17-32
8. Klein BE, Lein R. Cataracts and macular degeneration in older Americans. Arch Ophthalmol 1982; 100: 571-3
9. Gibson JM, Rosenthal AR, Lavery J. A study of the prevalence of eye disease in the elderly in an English community. Trans Ophthalmol Soc UK 1985; 104: 196-203
10. Jonasson F, Thordarson K. Prevalence of ocular disease and blindness in a rural area in the eastern region of Iceland during 1980 through 1984. Acta Ophthalmol Suppl 1987; 182: 44-7
11. Martinez GS, Campbell AJ, Reinken J, et al. Prevalence of ocular disease in a population study of subjects 65 years old and older. Am J Ophthalmol 1982; 94 (2): 181-9
12. Wu L. Study of aging macular degeneration in China. Jpn J Ophthalmol 1987; 31 (3): 349-67
13. Vinding T. Age-related macular degeneration: macular changes, prevalence and sex ratio: an epidemiological study of 1000 aged individuals. Acta Ophthalmol (Copenh) 1989; 67 (6): 609-16
14. Vingerling JR, Dielemans I, Hofman A, et al. The prevalence of age-related maculopathy in the Rotterdam Study. Ophthalmology 1995; 102 (2): 205-10
15. Mitchell P, Smith W, Attebo K, et al. Prevalence of age-related maculopathy in Australia: the Blue Mountains Eye Study. Ophthalmology 1995; 102 (10): 1450-60
16. Reidy A, Minassian DC, Vafidis G, et al. Prevalence of serious eye disease and visual impairment in a north London population: population based, cross sectional study. BMJ 1998; 316 (7145): 1643-6
17. VanNewkirk MR, Nanjan MB, Wang JJ, et al. The prevalence of age-related maculopathy: the visual impairment project. Ophthalmology 2000; 107 (8): 1593-600
18. Evans J, Wormald R. Is the incidence of registrable age-related macular degeneration increasing? Br J Ophthalmol 1996; 80 (1): 9-14
19. Dickinson AJ, Sparrow JM, Duke AM, et al. Prevalence of age-related maculopathy at two points in time in an elderly British population. Eye 1997; 11 (Pt 3): 315-24
20. Macular Photocoagulation Study Group. Laser photocoagulation of subfoveal neovascular lesions in age-related macular degeneration: results of a randomized clinical trial. Arch Ophthalmol 1991; 109: 1220-31
21. Macular Photocoagulation Study Group. Visual outcome after laser photocoagulation for subfoveal choroidal neovascularization secondary to age-related macular degeneration: the influence of initial lesion size and initial visual acuity. Arch Ophthalmol 1994; 112: 480-8
22. Ciulla TA, Danis RP, Harris A. Age-related macular degeneration: a review of experimental treatments. Surv Ophthalmol 1998; 43: 134-46
23. Soubrane G, Coscas G. Experimental therapies for age-related macular degeneration. Dev Ophthalmol 1997; 29: 78-84
24. Treatment of age-related macular degeneration with photodynamic therapy study group: photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin. Arch Ophthalmol 1999; 117 (10): 1329-45
25. Husain D, Miller W. Photodynamic therapy of exudative age-related macular degeneration: seminars in ophthalmology. Semin Ophthalmol 1997; 12 (1): 14-25
26. Scott LJ, Goa KL. Verteporfin. Drugs Aging 2000; 16 (2): 139-46
27. Chaine G, Hullo A, Sahel J, et al. Case-control study of the risk factors for age-related macular degeneration. France-DMLA Study Group. Br J Ophthalmol 1998; 82 (9): 996-1002
28. Klein R, Klein BE, Jensen SC, et al. The relationship of ocular factors to the incidence and progression of age-related maculopathy. Arch Ophthalmol 1998; 116 (4): 506-13
29. Hirvela H, Luukinen H, Laara E, et al. Risk factors of age-related maculopathy in a population 70 years of age or older. Ophthalmology 1996; 103 (6): 871-7
30. Delcourt C, Cristol JP, Tessier F, et al. Age-related macular degeneration and antioxidant status in the POLA study. POLA study Group. Pathologies Oculaires Liées à l'Age. Arch Ophthalmol 1999; 117 (10): 1384-90
31. Vingerling JR, Klaver CC, Hofman A, et al. Epidemiology of age-related maculopathy. Epidemiol Rev 1995; 17 (2): 347-60
32. Delcourt C, Diaz JL, Ponton-Sanchez A, et al. Smoking and age-related macular degeneration. The POLA Study. Pathologies Oculaires Liées à l'Age. Arch Ophthalmol 1998; 116 (8): 1031-5
33. Bressler SB, Bressler NM, Fine SL, et al. Natural course of choroidal neovascular membranes within the foveal avascular zone in senile macular degeneration. Am J Ophthalmol 1982; 93 (2): 157-63
34. Bressler SB, Bressler NM, Fine SL. Age-related macular degeneration. Surv Ophthalmol 1988; 32 (6): 375-413
35. Fine SL, Berger JW, Maguire MG, et al. Age-related macular degeneration. N Engl J Med 2000; 342 (7): 483-92
36. Vidal 2000. Available from URL: http://www.vidal.fr/ [Accessed 2002 Dec 6]
37. Programme Médicalisé des Systèmes d'Information. French Ministry of Health database. Paris: French Ministry of Health, 2000. Available from http://www.le-pmsi.fr [Accessed 2002 Dec 6]
38. Nomenclature générale des actes professionnels et nomenclature des actes de biologie médicale - Union des caisses nationales de sécurité sociale (UCANSS). Paris: Union des caisses nationales de sécurité sociale, 2000
39. Tarif interministeriel des prestations sanitaires. Paris: Union des Caisses Nationales de Sécurité Sociale, 2001
40. Brown GC, Brown MM, Sharma S et al. Incremental cost-effectiveness of laser photocoagulation for subfoveal choroidal neovascularization. Ophthalmology 2000; 107 (7): 1374-80
41. Sharma S, Brown GC, Brown MM et al. The cost-effectiveness of photodynamic therapy for fellow eyes with subfoveal choroidal neovascularization secondary to age-related macular degeneration. Ophthalmology 2001; 108 (11): 2051-9
42. Alignon A, Com-Ruelle L, Dourgnon P, et al. La consommation médicale en 1997 selon les caractéristiques individuelles. Données de l'appariemment EPAS - ESPS. Paris: CREDES 2000. Report no. 1345
43. Le Pen C, Wait S, Moutard-Martin F, et al. Cost of illness and disease severity in a cohort of French patients with Parkinson's disease. Pharmacoeconomics 1999; 16 (1): 59-69